StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Somil Mehta, Sharekhan

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))26 Oct 2026via CNBC Awaaz.

Entry₹1,154.3Inferred
Target₹1,200
Total upside +3.96% (call closed)
Stop loss₹1,128-2.28% risk
Exit₹1,128Stop-loss hit — time not yet verified
Stop-loss hit-2.28%
Follow Somil Mehta for new calls(21% target hit, 253 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 54 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 1:34 pm IST
9 supporting1 neutral5 opposing
Supports the BUY call (9)

3 advisors have active intraday BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·26 Oct · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · 4d ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 5d ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 5d ago

(opens in new tab)
Neutral / worth noting (1)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 9 days

(opens in new tab)
Weighs against the BUY call (5)

Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant

NewsNdtv-Profit·26 Oct · today

(opens in new tab)

MACD below its signal line — bearish momentum

Technicals · macd·26 Oct · today

Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations

NewsCnbc-Tv18·13 Oct · 2w ago

(opens in new tab)

The USFDA concluded an inspection of Zydus Lifesciences' Moraiya manufacturing plant with 5 observations, which the company intends to address.

NSE · Press Release·13 Oct · 2w ago

(opens in new tab)

The USFDA concluded an inspection of the company's Moraiya manufacturing plant with 5 observations.

BSE · Company Update·13 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Somil Mehta, Sharekhan

Every call and its outcome